Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Titel:
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
Auteur:
Goldschmidt, Hartmut Mai, Elias K Bertsch, Uta Fenk, Roland Nievergall, Eva Tichy, Diana Besemer, Britta Dürig, Jan Schroers, Roland von Metzler, Ivana Hänel, Mathias Mann, Christoph Asemissen, Anne M Heilmeier, Bernhard Weinhold, Niels Huhn, Stefanie Kriegsmann, Katharina Luntz, Steffen P Holderried, Tobias A W Trautmann-Grill, Karolin Gezer, Deniz Klaiber-Hakimi, Maika Müller, Martin Khandanpour, Cyrus Knauf, Wolfgang Scheid, Christof Munder, Markus Geer, Thomas Riesenberg, Hendrik Thomalla, Jörg Hoffmann, Martin Raab, Marc S Salwender, Hans J Weisel, Katja C